Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
DESIGN: This single center, double-blinded, randomized phase II study is being conducted to
assess the efficacy of a rifabutin based regimen to eliminate S. aureus colonization in HIV
infected individuals. Individuals must have HIV infection and a skin and skin structure
infection (SSSI) in the prior 6 months to be eligible for screening. Prior to enrollment,
subjects will be cultured for evidence of S. aureus colonization. Individuals who are culture
positive at ≥ one body site will be eligible for enrollment. Subjects who meet inclusion and
exclusion criteria and consent to participate in the study will be randomized to seven days
of rifabutin plus trimethoprim-sulfamethoxazole (TMP-SMX) or TMP-SMX alone. Following
completion of treatment subjects will be screened seven days, 30 days, and 60 days
post-treatment for colonization at multiple body-sites. Subjects will also be actively
followed for evidence of SSSI.
SUBJECT PARTICIPATION DURATION: 12 weeks
SAMPLE SIZE: 88 total subjects
POPULATION: 200 HIV infected individuals who receive care at San Francisco General Hospital
HIV clinic (Ward 86) with a history of SSSI in the prior 6 months will be screened for S.
aureus colonization.
DESCRIPTION OF AGENT OR INTERVENTION: This is a double-blind trial comparing rifabutin plus
TMP-SMX versus placebo plus TMP-SMX. Placebo will be administered at a dose of 300 mg p.o.
daily or an equivalent dose depending on co-administration of other drugs that may adjust the
serum level of rifabutin. TMP-SMX will be administered at a dose of trimethoprim 160 mg and
sulfamethoxazole 800 mg p.o. twice daily or adjusted per CrCl. Study drug will be provided by
the study and administered for 7 days.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Treatments:
Rifabutin Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination